Neoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in Melanoma: NEO-VC
Status:
Terminated
Trial end date:
2020-05-14
Target enrollment:
Participant gender:
Summary
Evaluation of the efficacy, safety and biologic effects of neo-adjuvant treatment with
vemurafenib + cobimetinib + atezolizumab in patients with limited metastasis of melanoma in
stage IIIC/IV melanoma.